Huma This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
UK medtech startup Huma has raised $130 million from German pharma giant Bayer and Hitachi Ventures.
CEO Dan Vahdat says the exciting part of the health tech industry has not yet started.
The industry has been tipped to save up to $3 trillion a year in medical costs by 2030.
A medical technology that aims to place mini hospitals in everyone s pocket has raised $130 million to help fund its push into US, Asia, and the Middle East.
London-based Huma, previously known as Medopad, has raised the funds from a host of big names including German pharma giant Bayer, and the venture funding arm of Japanese tech giant Hitachi.
Founded in 2011 as Medopad, Huma s software lets clinicians monitor patients remotely through a mobile app. It also uses a range of wearables and other devices to gather data on things like heart rate and oxygen saturation.
The start-up claims it s able to pick up on deteriorations in patients health status and decide whether they should go to the hospital or not. The other side of Huma s business focuses on academic research.
The company works with Britain s National Health Service and governments in Germany and the United Arab Emirates. Dan Vahdat, Huma s CEO and co-founder, said the firm had offered its services to the NHS pro bono during the Covid-19 crisis.
(1)
LONDON and NEW YORK, March 11, 2021 /PRNewswire/ Huma s exponential growth in healthcare and lifesciences across Europe has been recognised by the
Financial Times. Huma is leading healthcare and life sciences expansion with four national deals for its hospital at home digital wards (Germany, England, Wales, UAE).
Across all sectors, Huma has been selected as the 23rd fastest-growing company in Europe
[1], on the published list of 1,000. The London-based start-up provides a modular remote monitoring platform to run digital hospitals at home . This technology also powers research in the US and across Europe, including some of the world s largest decentralized clinical trials on illnesses ranging from atrial fibrillation to diabetes to Covid-19.
We all know by now that the gloomsters were wrong. Mumps was previously the fastest effort ever, from virus to vaccine in four years. This time around, it took just months. But while the speed of discovery and the 90 per cent-plus demonstrations of efficacy will play a key role in ending this pandemic, the development of a whole new way of making vaccines could also prevent future outbreaks. At the Future Vaccine Manufacturing Hub, Imperial College London, Zoltan Kis says RNA vaccines will make humanity safer . They work not in the traditional method of injecting people with an inactive version of the virus, but by introducing genetic code that teaches the body to build its own, harmless version of it - in Covid s case, the infamous spike protein. That preps the immune system against future infection. Kis describes the process as teaching the body a new skill .
How the coronavirus pandemic will transform healthcare
Despite Covid’s dreadful toll, this crisis has also driven some extraordinary medical breakthroughs
27 December 2020 • 5:00pm
Margaret Keenan was the first patient in the UK to receive the Covid vaccine
Credit: Jacob King/PA
Historians looking back on 2020 may well write it off as a medical catastrophe – a year of infamy to rank along 1918’s Spanish Flu; a modern plague to rival that of 1665. “Great fears of the Sickenesse here in the City,” Pepys wrote in April that year. “God preserve us all.”
But alongside Covid’s dreadful toll, this crisis has also driven extraordinary medical breakthroughs. What was thought impossible has been proven possible; the merely difficult has become routine; cumbersome old ways of treating patients have been swept aside. Healthcare has been stood on its head. It has not all been positive, but a host of benefits have undoubtedly emerged. Here are a few areas of positivity: